Peptides DB
Research-centric peptide and protocol reference hub
Study 25 of 25Goserelin literatureUrology case reports · Case report2026

Isolated testicular metastasis as a rare manifestation of castration-resistant prostate cancer.

This case illustrates the importance of <sup>68</sup>Ga-PSMA PET/CT in detecting rare testicular metastases from prostate cancer, with the patient achieving undetectable PSA levels after surgery.

Read at Urology case reportsAdd to compare

Where it sits

this study against the rest of the goserelin corpus
4
Preclinical
15
Observational · this one
0
Open-label
5
Randomised
1
Reviews

Summary and findings

This case report describes a 65-year-old male with isolated testicular metastasis from prostate cancer detected by <sup>68</sup>Ga-PSMA PET/CT. The patient was maintained on goserelin depot and achieved complete biochemical remission by 6 weeks postoperatively. PSA levels decreased to undetectable levels (<0.1 ng/mL).

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
<0.1 ng/mL PSA at 6 weeks postoperatively.n=12026

Abstract

The authors’ words, as Urology case reports supplied them

Secondary testicular metastasis from prostate cancer is exceptionally rare. We report an isolated testicular recurrence detected by <sup>68</sup>Ga-PSMA PET/CT in a 65-year-old male with biochemical progression (PSA 2.5 ng/mL) during castration resistance. Conventional imaging was negative, but <sup>68</sup>Ga-PSMA PET/CT revealed a right testicular lesion (SUV<sub>max</sub> 21.8). Right radical inguinal orchiectomy confirmed metastatic Grade Group 5 prostate adenocarcinoma. Maintained on goserelin depot, the patient achieved complete biochemical remission by 6 weeks postoperatively, with an undetectable PSA (<0.1 ng/mL) and castrate testosterone (16 ng/dL). <sup>68</sup>Ga-PSMA PET/CT is crucial for uncovering occult atypical metastases, while radical orchiectomy provides essential cytoreduction and definitive histopathological diagnosis.

Background

Secondary testicular metastasis from prostate cancer is exceptionally rare, and conventional imaging often fails to detect such occurrences. Prior studies have highlighted the utility of <sup>68</sup>Ga-PSMA PET/CT in identifying atypical metastases. This case illustrates the importance of advanced imaging techniques in detecting isolated testicular metastasis in patients with biochemical progression during castration resistance.

Methods

This is a case report involving a 65-year-old male with biochemical progression of prostate cancer. The patient underwent <sup>68</sup>Ga-PSMA PET/CT imaging, which revealed a right testicular lesion, and subsequently had a right radical inguinal orchiectomy. The primary outcome measured was the biochemical remission indicated by PSA levels post-surgery.

Results

The primary endpoint observed was an undetectable PSA level (<0.1 ng/mL) at 6 weeks postoperatively. The right testicular lesion was confirmed as metastatic Grade Group 5 prostate adenocarcinoma. The patient maintained on goserelin depot achieved castrate testosterone levels of 16 ng/dL.

Interpretation

This case adds to the limited literature on isolated testicular metastasis from prostate cancer, suggesting that advanced imaging can reveal atypical sites of metastasis. However, the clinical significance of the findings is limited by the small sample size and the nature of a single case report. The results imply that while goserelin may play a role in managing hormone levels, the evidence presented does not establish its efficacy in this specific context.

Key findings

  • PSA 2.5 ng/mL at the time of detection.
  • SUV<sub>max</sub> 21.8 for the right testicular lesion.
  • Undetectable PSA (<0.1 ng/mL) at 6 weeks postoperatively.
  • Castrate testosterone level of 16 ng/dL post-surgery.

Limitations

  • Single case report limits generalizability.
  • No statistical analysis provided.
  • Short follow-up period of 6 weeks.
  • No control group for comparison.

Elsewhere in the Goserelin corpus

AAssessing the Feasibility of a Self-Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus.Cancer medicine · 2026 · n=28 · > 75% engagement and average acceptability score of 37.3/56.HumanBFrom Treatment Discontinuation to Aggressive Recurrence: A Cautionary Case Report of Rapid Progression to Invasive Carcinoma Following Torimifene-Induced Hepatotoxicity and Drug Withdrawal in a Patient With Completely Resected Intraductal Papillary Carcinoma.Clinical case reports · 2026 · n=1HumanAImpact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.The Canadian journal of urology · 2026 · n=174 · Not reported in abstract.HumanBDrug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology.Expert opinion on drug safety · 2025 · n=33948 · Median weight for GLP-1 analogues was 91 kg, and for compound hypoglycemic agents was 82 kg, p < 0.01.reviewBClinical pathological changes in prostate cancer patients after hormonal therapy: A single-center pilot study.Biochemistry and biophysics reports · 2026 · n=32 · Corrected mean AUC was 0.725 (95% CI: 0.58-0.87).HumanAFovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.JAMA oncology · 2026 · n=417 · Median PFS not reached vs 20.2 months with placebo, HR 0.55, 95% CI 0.38-0.77, 1-sided P < .001.Human